AN UPDATE ON ANTI-AGING DRUG TRIALS

A dramatic advance in the field of aging occurred when animal models where targeted by genetic, environmental, or pharmacological interventions, and their life span was extended. Some of these drugs are approved for use in human conditions but not for aging specifically. Several kinds of efforts hav...

Full description

Saved in:
Bibliographic Details
Published in:Innovation in aging 2018-11, Vol.2 (suppl_1), p.544-544
Main Author: Barzilai, N
Format: Article
Language:English
Subjects:
Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A dramatic advance in the field of aging occurred when animal models where targeted by genetic, environmental, or pharmacological interventions, and their life span was extended. Some of these drugs are approved for use in human conditions but not for aging specifically. Several kinds of efforts have been launched to help the transition to aging-targeting drug trials in humans. A large clinical trial, TAME (Targeting Aging with MEtformin) will demonstrate the proof of concept that aging can be targeted; but more important, it will lead to such FDA indication. In academia several trials have been designed to test drugs such as metformin and acarbose based therapy in the elderly and to discover biomarkers from blood components, muscle, and adipose to be able to be followed up later in larger clinical trials. Finally, pharmaceutical efforts to devolve better and safer drugs (such as a rapamycin analogue) are beginning to take place with the hope that aging will become a prominent target to improve health-span and the economy.
ISSN:2399-5300
2399-5300
DOI:10.1093/geroni/igy023.2007